Key result
Renin-angiotensin-aldosterone system inhibitors, particularly ACE inhibitors and ARBs, may reduce the incidence of new-onset type 2 diabetes and offer cardiovascular and renal protection.
Why the study?
Do RAAS inhibitors reduce the incidence of new-onset type 2 diabetes mellitus and provide cardiovascular and renal protection?
Do RAAS inhibitors reduce the incidence of new-onset type 2 diabetes mellitus and provide cardiovascular and renal protection?
RAAS inhibitors may offer benefits beyond blood pressure lowering by reducing the risk of new-onset type 2 diabetes and providing cardiovascular and renal protection.
Answers are grounded in this paper and cite their sources.
Supports RAAS inhibitor benefits beyond BP lowering; leaves open confirmatory RCTs for new-onset diabetes prevention.
Hypertension increases the risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease. In addition to lowering blood pressure, blockade of the renin-angiotensin-aldosterone system (RAAS) reduces the risk of new-onset T2DM and offers renal protection. Using a MEDLINE search, we identified multiple trials that reported the incidence of T2DM in patients taking inhibitors of RAAS. In this review, we will discuss the RAAS as a potential target in diabetes prevention and the mechanisms through which inhibitors of this system achieve such an important effect. We will also shed light on the beneficial cardiovascular and renal effects of RAAS blockade. Although multiple studies have demonstrated that inhibitors of RAAS, especially angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, can reduce the incidence of T2DM, randomized controlled studies are still needed to further elucidate their exact role in diabetes prevention.
No takes yet. Share an insight, caveat, or question.
Abuissa et al. (2008) conducted a review in Hypertension, Type 2 Diabetes Mellitus. Renin-angiotensin-aldosterone system (RAAS) inhibitors was evaluated on Incidence of type 2 diabetes mellitus. Renin-angiotensin-aldosterone system inhibitors, particularly ACE inhibitors and ARBs, may reduce the incidence of new-onset type 2 diabetes and offer cardiovascular and renal protection.
Synapse has enriched 10 related papers. Consider them for comparative context: